Sora Linder 1 * , Kristina Bolten 2 , Zsuzsanna Varga 3 , Hisham Fansa 4
Correspondence: sora.linder@spitalzollikerberg.ch
Show More
[1]Largo RD, Tchang LA, Mele V, Scherberich A, Harder Y, Wettstein R et al. Efficacy, safety and complications of autologous fat grafting to healthy breast tissue: a systematic review. Journal of Plastic, Reconstructive, Aesthetic Surgery. 2014; 67:437-448. doi: 10.1016/j.bjps.2013.11.011.
[2]Spear SL, Coles CN, Leung BK, Gitlin M, Parekh M, Macarios D. The Safety, Effectiveness, and Efficiency of Autologous Fat Grafting in Breast Surgery. Plastic and Reconstructive Surgery Global Open. 2016;4:e827. doi: 10.1097/GOX.0000000000000842.
[3]Coleman SR, Saboeiro AP. Fat grafting to the breast revisited: safety and efficacy. Plastic and Reconstructive Surgery. 2007; 119:775-785. doi: 10.1097/01.prs.0000252001.59162.c9.
[4]Petit JY, Rietjens M, Botteri E, Rotmensz N, Bertolini F, Curigliano G et al. Evaluation of fat grafting safety in patients with intraepithelial neoplasia: a matched-cohort study. Annals of Oncology. 2013; 24:1479-1484. doi: 10.1093/annonc/mds660.
[5]Petit JY, Maisonneuve P, Rotmensz N, Bertolini F, Rietjens M. Fat Grafting after Invasive Breast Cancer: A Matched Case-Control Study. Plastic and Reconstructive Surgery. 2017 Jun;139(6):1292-1296. doi: 10.1097/PRS.0000000000003339. PMID: 28538546.
[6]Gutowski KA. ASPS Fat Graft Task Force. Current applications and safety of autologous fat grafts: a report of the ASPS fat graft task force. Plastic and Reconstructive Surgery. 2009 Jul;124(1):272-280. doi: 10.1097/PRS.0b013e3181a09506. PMID: 19346997.
[7]Dalay E, Garson S, Tousson G, Sinna R. Fat injection to the breast: technique, results and indications based on 880 procedures over 10 years. Aesthetic. Surgery Journal. 2009; (29) 360-376. doi: https://doi.org/10.1016/j.asj.2009.08.010.
[8]Page DL, Salhany KE, Jensen RA, Dupont WD. Subsequent breast carcinoma risk after biopsy with atypia in a breast papilloma. Cancer. 1996 Jul 15;78(2):258-66.doi: 10.1002/(SICI)1097-0142(19960715)78:2<258:AID-CNCR11>3.0.CO;2-V. PMID: 8674001.
[9]Eiada R, Chong J, Kulkarni S, Goldberg F, Muradali D. Papillary lesions of the breast: MRI, ultrasound, and mammographic appearances. American Journal of Roentgenology. 2012 Feb;198(2):264-71. doi: 10.2214/AJR.11.7922. PMID: 22268167.
[10]AGO-Online. Laesionen unsicheres Potential. Available from https://www.agoonline.de/fileadmin/agoonline/downloads/_leitlinien/kommission_mamma/2021/Einzeldateien/2021D_06_Laesionen_unsicheres_Potential_MASTER_final_20210301.pdf
[11]Rageth CJ, O'Flynn EAM, Pinker K, Kubik-Huch RA, Mundinger A, Decker T et al. Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast Cancer Research and Treatment. 2019 Apr;174(2):279-296. doi: 10.1007/s10549-018-05071-1.
[12]Rizzo M, Lund MJ, Oprea G, Schniederjan M, Wood WC, Mosunjac M. Surgical follow-up and clinical presentation of 142 breast papillary lesions diagnosed by ultrasound-guided core-needle biopsy. Annals of Surgical Oncology. 2008 Apr;15(4):1040-7. doi: 10.1245/s10434-007-9780-2.
[13]Ashkenazi I, Ferrer K, Sekosan M, Marcus E, Bork J, Zaren HA. Papillary lesions of the breast discovered on percutaneous large core and vacuum-assisted biopsies: reliability of clinical and pathological parameters in identifying benign lesions. American Journal of Surgery. 2007 Aug;194(2):183-8. doi: 10.1016/j.amjsurg.2006.11.028.
Copyright © 2023 Sora Linder, Kristina Bolten, Zsuzsanna Varga, Hisham Fansa
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright licenses detail the rights for publication, distribution, and use of research. Open Access articles published by Luminescience do not require transfer of copyright, as the copyright remains with the author. In opting for open access, the author(s) should agree to publish the article under the CC BY license (Creative Commons Attribution 4.0 International License). The CC BY license allows for maximum dissemination and re-use of open access materials and is preferred by many research funding bodies. Under this license, users are free to share (copy, distribute and transmit) and remix (adapt) the contribution, including for commercial purposes, providing they attribute the contribution in the manner specified by the author or licensor.
Luminescience press is based in Hong Kong with offices in Wuhan and Xi'an, China.
E-mail: publisher@luminescience.cn